REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
23 hedge funds and large institutions have $15.5M invested in REVIVA PHARMA HLDGS INC in 2023 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 11 increasing their positions, 2 reducing their positions, and 5 closing their positions.
450% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 2
407% more call options, than puts
Call options by funds: $12.5M | Put options by funds: $2.47M
170% more capital invested
Capital invested by funds: $5.76M → $15.5M (+$9.77M)
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
10% more funds holding
Funds holding: 21 → 23 (+2)
6.09% more ownership
Funds ownership: 6.73% → 12.82% (+6.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.22M |
| 2 |
Millennium Management
New York
|
+$2.67M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$505K |
| 4 |
CG
Colony Group
Boston,
Massachusetts
|
+$393K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$267K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
EMC Capital Management
Houston,
Texas
|
-$729K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$463K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$223K |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
-$181K |
| 5 |
Bank of New York Mellon
New York
|
-$63K |
RVPH Hedge Fund Activity: Q2 2023 in Review
23 of the 6,385 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q2 2023, worth a combined $15.5M — up 170% from $5.76M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new RVPH positions and 5 closed out — a net gain of 2 holders — while 11 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $5.22M. The largest seller was EMC Capital Management, cutting an estimated $729K.
- 23 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q2 2023, up from 21 in Q1 2023.
- Funds reported $15.5M of REVIVA PHARMA HLDGS INC stock for Q2 2023, up 170% quarter-over-quarter.
- 7 funds opened new REVIVA PHARMA HLDGS INC positions in Q2 2023 and 5 closed out, a net change of +2 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q2 2023 was Armistice Capital, an estimated $5.22M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q2 2023 was EMC Capital Management, an estimated $729K sold.
Based on aggregated 13F filings for Q2 2023.